Adults 18 to 99, any sex, with Hemianopia, Homonymous or Hemianopsia, Homonymous. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Humphrey Visual Field PerimetryPrimary· Baseline
The area of the subject's visual field measured by 30-2 Humphrey visual field (HVF) perimetry. Both left and right sides will be tested. The deficit side includes is the hemianopic side. The intact side is the non-hemianopic side. During the HVF test, light is projected into a white bowl with a standardized background light intensity to form a circular stimulus, around 30 cm away from the patient's eye. The overall field mapping technique used is a form of static perimetry, where a stimulus appears in various areas of the field of vision. The patient indicates when they can see the stimulus an
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
108
± 198.49
Virtual Reality (VR) Treatment-Intact
1272
± 117.58
Humphrey Visual Field PerimetryPrimary· up to 2 Months
The area of the subject's visual field measured by 30-2 Humphrey visual field (HVF) perimetry. Both left and right sides will be tested. The deficit side includes is the hemianopic side. The intact side is the non-hemianopic side. During the HVF test, light is projected into a white bowl with a standardized background light intensity to form a circular stimulus, around 30 cm away from the patient's eye. The overall field mapping technique used is a form of static perimetry, where a stimulus appears in various areas of the field of vision. The patient indicates when they can see the stimulus an
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
594
± 542.99
Virtual Reality (VR) Treatment-Intact
1356
± 18.59
Virtual Reality (VR) Visual Field Test--Mean Percent CorrectPrimary· Day 1
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
0
± 0
Virtual Reality (VR) Treatment-Intact
91.667
± 11.785
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.33
± 11.785
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 2
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
16.667
± 23.57
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
0
± 0
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 3
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.333
± 11.785
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
0
± 0
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 4
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
0
± 0
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
0
± 0
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 5
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
0
± 0
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.333
± 11.785
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 6
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
50
± 70.711
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.333
± 11.785
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 7
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
58.333
± 35.355
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.333
± 11.785
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 9
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
50
± 70.711
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.333
± 11.785
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 10
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
50
± 70.711
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.333
± 11.785
Virtual Reality (VR) Treatment-Intact
100
± 0
Virtual Reality Visual Field Test--Mean Percent CorrectPrimary· Day 12
Percent of correct trials in each location tested. Location at 15 degrees and 30 degrees on the horizontal meridian on both the left and right side were tested. Virtual Reality Visual Field test is a brief 5-minute test using the VR system to track rehabilitation progress. The test consists of 30 trials with visual stimulus presented either 15° or 30° in either the hemianopia field or the intact field at random time intervals.
15 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
50
± 70.711
Virtual Reality (VR) Treatment-Intact
100
± 0
30 Degrees
Group
Value
95% CI
Virtual Reality (VR) Treatment--Deficit Eye
8.33
± 11.785
Virtual Reality (VR) Treatment-Intact
91.667
± 11.785
Sponsor's own description
The purpose of this research study is to investigate the effectiveness of a new rehabilitation for visual hemianopia. The study team believes a cross-modal rehabilitation technique delivered by a virtual reality system can help restore the visual field for subjects with homonymous hemianopia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 30 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04230486.